FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Štefánik, M.; Valdés, James J.; Ezebuo, F.C.; Haviernik, J.; Uzochukwu, I.C.; Fojtiková, M.; Salát, J.; Eyer, Luděk; Růžek, Daniel

doi:https://dx.doi.org/10.3390/microorganisms8040599

Number of the records: 1

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

1.

SYSNO ASEP	0540544
Document Type	J - Journal Article
R&D Document Type	Journal Article
Subsidiary J	Článek ve WOS
Title	FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
Author(s)	Štefánik, M. (CZ) Valdés, James J. (BC-A)_{RID, ORCID} Ezebuo, F.C. (NG) Haviernik, J. (CZ) Uzochukwu, I.C. (NG) Fojtiková, M. (CZ) Salát, J. (CZ) Eyer, Luděk (BC-A)_{RID, ORCID} Růžek, Daniel (BC-A)_{RID, ORCID}
Number of authors	9
Article number	599
Source Title	Microorganisms. - : MDPI Roč. 8, č. 4 (2020)
Number of pages	17 s.
Publication form	Online - E
Language	eng - English
Country	CH - Switzerland
Keywords	nucleoside inhibitors ; virus ; protein ; screen ; pele ; fda ; flavivirus ; Zika virus ; tick-borne encephalitis virus ; West Nile virus ; antiviral
Subject RIV	EE - Microbiology, Virology
OECD category	Microbiology
R&D Projects	NV16-34238A GA MZd - Ministry of Health (MZ)
Method of publishing	Open access
Institutional support	BC-A - RVO:60077344
UT WOS	000533510400128
EID SCOPUS	85084005221
DOI	10.3390/microorganisms8040599
Annotation	Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested, i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.
Workplace	Biology Centre (since 2006)
Contact	Dana Hypšová, eje@eje.cz, Tel.: 387 775 214
Year of Publishing	2021
Electronic address	https://www.mdpi.com/2076-2607/8/4/599

Number of the records: 1